Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria
The emergence of infections caused by bacterial pathogens that are resistant to current antibiotic therapy is a critical healthcare challenge. Aminoglycosides are natural antibiotics with broad spectrum of activity; however, their clinical use is limited due to considerable nephrotoxicity. Moreover,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fmicb.2020.01718/full |
| _version_ | 1819007148094390272 |
|---|---|
| author | Jing Kong Zhuo-Xun Wu Liuya Wei Liuya Wei Zhe-Sheng Chen Sabesan Yoganathan |
| author_facet | Jing Kong Zhuo-Xun Wu Liuya Wei Liuya Wei Zhe-Sheng Chen Sabesan Yoganathan |
| author_sort | Jing Kong |
| collection | DOAJ |
| description | The emergence of infections caused by bacterial pathogens that are resistant to current antibiotic therapy is a critical healthcare challenge. Aminoglycosides are natural antibiotics with broad spectrum of activity; however, their clinical use is limited due to considerable nephrotoxicity. Moreover, drug-resistant bacteria that cause infections in human as well as livestock are less responsive to conventional antibiotics. Herein, we report the in vitro antibacterial evaluation of five different aminoglycosides, including ribostamycin, against a panel of Gram-positive and Gram-negative pathogens. Eight of the tested bacterial strains are linked to gastrointestinal (GI) infections. The minimum inhibitory concentration (MIC) of ribostamycin against three different Escherichia coli strains is in the range of 0.9–7.2 μM and against a strain of Haemophilus influenzae is 0.5 μM. We also found that the MIC of ribostamycin was considerably enhanced from 57.2 to 7.2 μM, an 8-fold improvement, when bacteria were treated with a combination of ribostamycin and ethylenediaminetetraacetic acid (EDTA). These findings demonstrate a promising approach to enhance the clinical potential of ribostamycin and provide a rational for its antibiotic reclassification from special level to non-restricted level. |
| first_indexed | 2024-12-21T00:19:58Z |
| format | Article |
| id | doaj.art-0963919ce6d246e7aa89c731be06a308 |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-12-21T00:19:58Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-0963919ce6d246e7aa89c731be06a3082022-12-21T19:22:07ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2020-07-011110.3389/fmicb.2020.01718561442Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic BacteriaJing Kong0Zhuo-Xun Wu1Liuya Wei2Liuya Wei3Zhe-Sheng Chen4Sabesan Yoganathan5Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York, NY, United StatesDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York, NY, United StatesDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York, NY, United StatesSchool of Pharmacy, Weifang Medical University, Weifang, ChinaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York, NY, United StatesDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York, NY, United StatesThe emergence of infections caused by bacterial pathogens that are resistant to current antibiotic therapy is a critical healthcare challenge. Aminoglycosides are natural antibiotics with broad spectrum of activity; however, their clinical use is limited due to considerable nephrotoxicity. Moreover, drug-resistant bacteria that cause infections in human as well as livestock are less responsive to conventional antibiotics. Herein, we report the in vitro antibacterial evaluation of five different aminoglycosides, including ribostamycin, against a panel of Gram-positive and Gram-negative pathogens. Eight of the tested bacterial strains are linked to gastrointestinal (GI) infections. The minimum inhibitory concentration (MIC) of ribostamycin against three different Escherichia coli strains is in the range of 0.9–7.2 μM and against a strain of Haemophilus influenzae is 0.5 μM. We also found that the MIC of ribostamycin was considerably enhanced from 57.2 to 7.2 μM, an 8-fold improvement, when bacteria were treated with a combination of ribostamycin and ethylenediaminetetraacetic acid (EDTA). These findings demonstrate a promising approach to enhance the clinical potential of ribostamycin and provide a rational for its antibiotic reclassification from special level to non-restricted level.https://www.frontiersin.org/article/10.3389/fmicb.2020.01718/fullantibioticaminoglycosidedrug resistanceEscherichia coliethylenediaminetetraacetic acidinfection |
| spellingShingle | Jing Kong Zhuo-Xun Wu Liuya Wei Liuya Wei Zhe-Sheng Chen Sabesan Yoganathan Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria Frontiers in Microbiology antibiotic aminoglycoside drug resistance Escherichia coli ethylenediaminetetraacetic acid infection |
| title | Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria |
| title_full | Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria |
| title_fullStr | Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria |
| title_full_unstemmed | Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria |
| title_short | Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria |
| title_sort | exploration of antibiotic activity of aminoglycosides in particular ribostamycin alone and in combination with ethylenediaminetetraacetic acid against pathogenic bacteria |
| topic | antibiotic aminoglycoside drug resistance Escherichia coli ethylenediaminetetraacetic acid infection |
| url | https://www.frontiersin.org/article/10.3389/fmicb.2020.01718/full |
| work_keys_str_mv | AT jingkong explorationofantibioticactivityofaminoglycosidesinparticularribostamycinaloneandincombinationwithethylenediaminetetraaceticacidagainstpathogenicbacteria AT zhuoxunwu explorationofantibioticactivityofaminoglycosidesinparticularribostamycinaloneandincombinationwithethylenediaminetetraaceticacidagainstpathogenicbacteria AT liuyawei explorationofantibioticactivityofaminoglycosidesinparticularribostamycinaloneandincombinationwithethylenediaminetetraaceticacidagainstpathogenicbacteria AT liuyawei explorationofantibioticactivityofaminoglycosidesinparticularribostamycinaloneandincombinationwithethylenediaminetetraaceticacidagainstpathogenicbacteria AT zheshengchen explorationofantibioticactivityofaminoglycosidesinparticularribostamycinaloneandincombinationwithethylenediaminetetraaceticacidagainstpathogenicbacteria AT sabesanyoganathan explorationofantibioticactivityofaminoglycosidesinparticularribostamycinaloneandincombinationwithethylenediaminetetraaceticacidagainstpathogenicbacteria |